Lowers the risk of cardiovascular mortality. ANDA 74453, held by Adaptis. Metoprolol Tartrate.
As of Nov 22, 2026, ANDA 74453 (Metoprolol Tartrate), held by Adaptis, was first approved by FDA on Apr 27, 1995, with 3 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Metoprolol tartrate tablets is a beta-adrenergic blocker indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 27, 1995 | Original application | Approved | None posted |
| Metoprolol Tartrate50MG · tablet;oral | Metoprolol Tartrate | Rx |
| Metoprolol Tartrate100MG · tablet;oral | Metoprolol Tartrate | Rx |
| Sep 3, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 3, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 3, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 27, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters